This study examined sequelae in 49 pediatric patients with invasive meningococcal disease (IMD) in Chile between 2009-2019. The researchers found that 59% of patients experienced sequelae at hospital discharge, with neurological disorders being the most common at 59.2%. Risk factors for sequelae included age under 1 year old, shock, and meningeal signs at admission. Sequelae were also associated with a clinical diagnosis of meningitis with meningococcemia. The study concludes that multidisciplinary follow-up is needed to reduce the long-term impacts of IMD in children.
Prospects for GBS prevention - current candidates & removing barriers to licensure of a GBS vaccine for pregnant women globally
https://www.meningitis.org/mrf-conference-2017
Prospects for GBS prevention - current candidates & removing barriers to licensure of a GBS vaccine for pregnant women globally
https://www.meningitis.org/mrf-conference-2017
Edward Cachay, MD, MAS
Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
DIAGNOSIS OF PEDIATRIC INFECTIOUS DISEASES - Slideset by professor Susanna Esposito, president WAidid, presented at the 7th International Congress of Laboratory and Clinic, held in Tehran (Iran) from 12 to 14 February 2015
This webinar is organized by MyICID and Institute for Clinical Research (ICR), NIH, Ministry of Health in conjunction with Neglected Tropical Disease Day 2022. The purpose of this webinar is to refresh and update our knowledge on Dengue fever, which has been overshadowed by COVID-19 since the beginning of the pandemic.
Presenter: Dr Norhayati Mokhtar, Public Health Physician at the Vector Borne Disease Sector, Disease Control Division, Ministry of Health Malaysia
#dengue #WorldNTDDay #BeatNTDs
This presentation was created and presented by Marta Busana from ECDC during the Invasive Bacterial Diseases laboratory network/ECDC Vaccine-preventable diseases network meeting in Barcelona, July 2012.
Determine the frequency of 16 high-risk conditions and associated complications in a Michigan state-wide network of academic and community EDs (MiPEM) during the COVID-19 pandemic
The health and safety of employees and contractors is a key consideration for any mining operation anywhere in the world. However, in a sustainable mining context these considerations cannot terminate at the front gate – the health and wellbeing of people in the communities surrounding mining operations are crucial for the success of the operations themselves.
Critical health issues facing communities vary around the world and how these issues are addressed also varies. What is consistent is the need to consider how the projects are affected by the local environments and the impacts projects may have on communities. And this must be done at every stage of the project lifecycle, from early exploration to resettlement and decommissioning.
Public health should be integral to any mining operation. The contexts in which projects are located generate health challenges that can have serious repercussions on the projects themselves, such as the current ebola outbreak in West Africa. At the same time, public health considerations should be the cornerstone of any corporate social responsibility (CSR) program. If well-conceived these programs can contribute to local development but often the existing health systems and regulations are not clearly understood
GetPersonalized! Estonian approach - from biobanking to precision medicine, A...Sitra / Hyvinvointi
Estonian approach - from biobanking to precision medicine, Andres Metspalu, Director, Estonian Genome Center, (Estonia), GetPersonalized! summit in Helsinki on 25 May 2015
NCCR 2020: Conference Of Very Important Disease (COVID-19) | 24 - 26 August 2020
Young Investigator Awards Presentation
Wan Shakira Bt Rodzlan Hasani
(Institute for Public Health, NIH)
https://doi.org/10.5281/zenodo.4004583
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Dr Rodolfo villena
1. “Sequelae at hospital discharge in 49 children
with invasive meningococcal disease. Chile,
2009-2019”.
november 2021
Cindy Arteta (1,2), Rodolfo Villena (1,3), María Elena Santolaya (1,2)
1. Faculty of Medicine Universidad de Chile, 2. Hospital de niños Dr Luis Calvo Mackenna 3. Hospital de
niños Dr Exequiel González Cortés
Contact: Rodolfo Villena. rvillena@uchile.cl
2. • Introduction
• “Defeating meningitis by 2030” is a goal of the World Health Organization
• To address the sequelae is one of the pillar for it
• Chilean study: overall IMD sequelae rate of 28% (MenB outbreak in 90s)
• Objective
• Describe the sequelae caused by IMD in pediatric patients
• Methods
• Cross-sectional study performed with medical records in two pediatric public
hospitals in Santiago, Chile
• Patients with diagnosis of IMD from 2009-2019 microbiologically confirmed were
included
• Bivariate analysis and logistic regression were performed
“Sequelae at hospital discharge in 49 children with
invasive meningococcal disease. Chile, 2009-2019”
3. Table 1. Socio-demographic data of children with IMD, Chile, 2009-2019
79,5%
98%
“Sequelae at hospital discharge in 49 children with
invasive meningococcal disease. Chile, 2009-2019”
Variables Total n=49 (%) Sequelae n=29 (%)
59%
No sequelae n=20 (%) p value
Age Median [IQR],
months
9 [4-27] 8.0 [4-23] 12.0 [4-82]
< 1 year old 28 (57.1) 18 (62.0) 10 (50.0) 0.40
1-4 years old 11 (22.4) 7 (24.1) 4 (20.0) 0.74
>5 years old 10 (20.4) 4 (13.7) 6 (30.0) 0.14
Gender Male 34 (69.3) 19 (65.5) 15 (75.0) 0.45
Socioeconomic
status
High 1 (2.0) 1 (3.4) 0 0.40
Middle 26 (53.0) 12 (41.3) 14 (70.0) 0.04
Low 22 (44.9) 16 (55.1) 6 (30.0) 0.08
Comorbidity Yes 16 (32.6) 9 (31.0) 7 (35.0) 0.76
Type of
comorbidity
Recurrent wheezing 9 (18.3) 5 (17.2) 4 (20.0) 0.78
Immunodeficiency 2 (4.0) 1 (3.4) 1 (5.0) 0.78
Prematurity 2 (4.0) 2 (6.9) 0 0.26
Neurological
disease
1 (2.0) 0 1 (5.0) 0.22
Congenital
cardiopathy
1 (2.0) 0 1 (5.0) 0.22
Obesity 4 (8.1) 3 (10.3) 1 (5.0) 0.52
Malnutrition 2 (4.0) 1 (3.4) 1 (5.0) 0.78
Results
4. Univariate Associations Logistic Regression analysis
Variable Total N 49 (%) Sequelae N 29
(%)
No sequelae 20
(%)
p value OR 95% CI
Onset of
symptoms before
consulting (days)
Median [IQR] 2.0 [1.0-4.0] 2.0 [1.0-3.0] 2.0 [1.0-3.0] 1 - -
Number of
medical visits
1 11 (22.4) 8 (27.5) 3 (15.0) 0.31
2 27 (55.1) 15 (51.7) 12 (60.0) 0.56
>3 11 (22.4) 6 (20.6) 5 (25.0) 0.67
Signs and
symptoms
Fever 49 (100) 29 (100) 20 (100) 1
Compromised general
condition
36 (73.4) 23 (79.3) 13 (65.0) 0.26 0.28 (0.03 – 2.56)
Shock 25 (51.0) 8 (27.5) 3 (15.0) 0.03 2.15 (0.49 – 9.41)
Vomiting 31 (63.2) 16 (55.1) 15 (75.0) 0.01 17.06 (1.74 – 166.94)
Diarrhea 14 (28.5) 8 (27.5) 6 (30.0) 0.84 1.62 (0.23 – 11.40)
Abdominal pain 6 (12.2) 2 (6.9) 4 (20.0) 0.16 0.29 (0.04 – 1.80)
Drowsiness/irritability 23 (46.9) 17 (58.6) 7 (35.0) 0.10 2.83 (0.39 – 20.44)
Meningeal signs 21 (42.8) 17 (58.6) 4 (20.0) 0.007 0.04 (0.00 – 0.55)
Neurological deficit 20 (40.8) 16 (55.1) 4 (20.0) 0.2 0.34 (0.07 – 1.56)
Headache 14 (28.5) 10 (34.4) 4 (20.0) 0.27 1.09 (0.16 – 7.28)
Seizures 3 (6.1) 2 (6.9) 1 (5.0) 0.78 - -
Petechiae/rash 20 (40.8) 12 (41.3) 8 (40.0) 0.92 0.66 (0.12 – 3.48)
Table 2. Clinical characteristics of invasive meningococcal disease by presents of sequelae in Chilean children during 2009-2019
Results
“Sequelae at hospital discharge in 49 children with invasive
meningococcal disease. Chile, 2009-2019”
5. Univariate Associations Logistic Regression analysis
Variable Total N 49 (%) Sequelae N 29 (%) No sequelae 20 (%) P value OR 95% CI
Clinical diagnosis Meningitis +
meningococcemia
19 (38.7) 17 (58.6) 2 (10.0) <0.001 12.75 (2.48 – 65.54)
Bacteremia 10 (20.4) 1 (3.4) 9 (45.0) <0.001 0.007 (0.00 – 0.21)
Septic arthritis 7 (14.2) 7 (24.1) 0 0.01
Meningitis 6 (12.2) 2 (6.9) 4 (20.0) 0.16 3.64 (0.31 – 41.65)
Meningococcemia 5 (10.2) 0 5 (25.0) 0.06 - -
Waterhouse
Friderichsen Syndrome
2 (4.0) 2 (6.9) 0 0.23 - -
Number of sequelae 1 19 (38.7) 19 (65.5) -
2 8 (16.3) 8 (27.5) -
3 2 (4.0) 2 (6.9) -
Type of sequelae* Neurological disorders 19 (38.7) 19 (65.5) -
Hearing loss 10 (20.0) 10 (34.4) -
Osteoarticular 9 (18.3) 9 (31.0) -
Skin scarring 3 (6.1) 3 (10.3) -
Post discharge
follow-up
Yes 34 (69) 27 (93.1) 7 (35.0) <0.001
N. meningitidis
serogroup
B 17 (34.6) 11 (37.9) 6 (30.0) 0.61
W 30 (61.2) 16 (55.1) 14 (70.0) 0.29
Table 2. Clinical characteristics of invasive meningococcal disease by presents of sequelae in Chilean children during 2009-2019
Results
“Sequelae at hospital discharge in 49 children with invasive
meningococcal disease. Chile, 2009-2019”
6. Table 3. Classification of sequelae in children with IMD
“Sequelae at hospital discharge in 49 children with
invasive meningococcal disease. Chile, 2009-2019”
Type of sequelae
Number of
sequelae: 54
%
Neurological disorders 32 59.2
Psychomotor developmental
delay
12 22.2
Speech-language
impairment
7 12.9
Seizures 5 9.2
Hypertonia/Hypotonia 5 9.2
Nerve damage 2 3.7
Attention deficit/
hyperactivity disorder
1 1.8
Hearing loss 10 18.5
Cochlear implant 2 3.7
Skin scarring 3 5.5
Osteoarticular 9 16.6
Movement limitation 6 11.1
Surgical debridement 2 3.7
Amputation 1 1.8
53%
27%
13%
7%
41%
18%
5%
36%
Sequelae of meningococcal disease by serogroup in Chilean children
Neurological
disorders
Hearing loss
Skin scarring
Osteoarticular
W
B
p 0.03
Figure 1. Sequelae of meningococcal disease by serogroup in chilean
children, 2009-2019
*
7. “Sequelae at hospital discharge in 49 children with
invasive meningococcal disease. Chile, 2009-2019”
2009-2013 2015-2019
Total 41 8
B 13 4
W 26 4
0
5
10
15
20
25
30
35
40
45
Cases
Sequelae by serogroup and time interval in peadiatrics
patients, Chile 2009-2019
p < 0.0001
*
*
*
8. • Invasive meningococcal disease remains as a public health concern
• A high rate of sequelae were found in pediatric patients in Chile (59%)
• Focus in < 1 yoa, shock and meningeal signs at admission
• Clinical manifestations: meningitis + meningococcemia
• Neurological sequelae were the most prevalent
• A multidisciplinary follow-up protocols to reduce their long-term impact
must be urgently established as a priority to assess all children and their
families with the aim to reduce the long-term consequences/impact of
IMD
Conclusions
“Sequelae at hospital discharge in 49 children with
invasive meningococcal disease. Chile, 2009-2019”
9. “Sequelae at hospital discharge in 49 children
with invasive meningococcal disease. Chile,
2009-2019”.
november 2021
Cindy Arteta (1,2), Rodolfo Villena (1,3), María Elena Santolaya (1,2)
1. Faculty of Medicine Universidad de Chile, 2. Hospital de niños Dr Luis Calvo Mackenna 3. Hospital de
niños Dr Exequiel González Cortés
Contact: Rodolfo Villena. rvillena@uchile.cl